These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33547392)

  • 1. Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma.
    Dufies M; Verbiest A; Cooley LS; Ndiaye PD; He X; Nottet N; Souleyreau W; Hagege A; Torrino S; Parola J; Giuliano S; Borchiellini D; Schiappa R; Mograbi B; Zucman-Rossi J; Bensalah K; Ravaud A; Auberger P; Bikfalvi A; Chamorey E; Rioux-Leclercq N; Mazure NM; Beuselinck B; Cao Y; Bernhard JC; Ambrosetti D; Pagès G
    Commun Biol; 2021 Feb; 4(1):166. PubMed ID: 33547392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
    Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The up-regulation of NDRG1 by HIF counteracts the cancer-promoting effect of HIF in VHL-deficient clear cell renal cell carcinoma.
    Zhang ZY; Zhang SL; Chen HL; Mao YQ; Li ZM; Kong CY; Han B; Zhang J; Chen YH; Xue W; Zhai W; Wang LS
    Cell Prolif; 2020 Jul; 53(7):e12853. PubMed ID: 32537867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
    Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
    Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
    Zuco V; De Cesare M; Zaffaroni N; Lanzi C; Cassinelli G
    Oncotarget; 2015 Apr; 6(11):8736-49. PubMed ID: 25826089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
    Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
    Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SEC14L3 knockdown inhibited clear cell renal cell carcinoma proliferation, metastasis and sunitinib resistance through an SEC14L3/RPS3/NFκB positive feedback loop.
    Jiang Z; Yang G; Wang G; Wan J; Zhang Y; Song W; Zhang H; Ni J; Zhang H; Luo M; Wang K; Peng B
    J Exp Clin Cancer Res; 2024 Oct; 43(1):288. PubMed ID: 39425205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma.
    Wang C; Wang Y; Hong T; Cheng B; Gan S; Chen L; Zhang J; Zuo L; Li J; Cui X
    Cell Death Dis; 2020 Feb; 11(2):117. PubMed ID: 32051393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells.
    Zhang G; Zhang Z; Liu Z
    Tumour Biol; 2013 Jun; 34(3):1887-94. PubMed ID: 23494182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DKC1 serves as a potential prognostic biomarker for human clear cell renal cell carcinoma and promotes its proliferation, migration and invasion via the NF‑κB pathway.
    Zhang M; Pan Y; Jiang R; Hou P; Shan H; Chen F; Jiang T; Bai J; Zheng J
    Oncol Rep; 2018 Aug; 40(2):968-978. PubMed ID: 29901172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas.
    Sakurai Y; Hatakeyama H; Akita H; Harashima H
    Mol Pharm; 2014 Aug; 11(8):2713-9. PubMed ID: 24800640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
    Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
    Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
    Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
    [No Abstract]   [Full Text] [Related]  

  • 14. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
    D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
    J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
    Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy.
    Rustum YM; Chintala S; Durrani FA; Bhattacharya A
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30380599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma.
    Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X
    Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A.
    Xiao W; Lou N; Ruan H; Bao L; Xiong Z; Yuan C; Tong J; Xu G; Zhou Y; Qu Y; Hu W; Gao Y; Ru Z; Liu L; Xiao H; Chen K; Yang H; Zhang X
    Cell Physiol Biochem; 2017; 43(6):2420-2433. PubMed ID: 29073615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tpl2 kinase impacts tumor growth and metastasis of clear cell renal cell carcinoma.
    Lee HW; Joo KM; Lim JE; Cho HJ; Cho HJ; Park MC; Seol HJ; Seo SI; Lee JI; Kim S; Jeong BC; Nam DH
    Mol Cancer Res; 2013 Nov; 11(11):1375-86. PubMed ID: 23982215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive profiling of circRNAs and the tumor suppressor function of circHIPK3 in clear cell renal carcinoma.
    Li H; Heng B; Ouyang P; Xie X; Zhang T; Chen G; Chen Z; Cheang K; Lai C
    J Mol Histol; 2020 Jun; 51(3):317-327. PubMed ID: 32409849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.